TME Pharma N.V. (EPA:ALTME)

France flag France · Delayed Price · Currency is EUR
0.0720
-0.0130 (-15.29%)
At close: Jan 30, 2026
-0.55%
Market Cap6.77M -2.3%
Revenue (ttm)27.00K
Net Income-4.58M
EPS-0.07
Shares Out94.09M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,579,009
Average Volume379,282
Open0.0726
Previous Close0.0850
Day's Range0.0664 - 0.0807
52-Week Range0.0490 - 0.1480
Beta0.75
RSI55.71
Earnings DateApr 23, 2026

About TME Pharma

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company’s Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It also developing NOX-E36, which has completed Phase 1/2a clinical trial for the treatme... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 12
Stock Exchange Euronext Paris
Ticker Symbol ALTME
Full Company Profile

Financial Performance

Financial Statements